Luxderm Specjalistyczny Gabinet Dermatologiczny

Lublin 10 trials 1 recruiting

10 Registered trials

1 Currently recruiting

Organisation

Luxderm Specjalistyczny Gabinet Dermatologiczny

Location

Lublin, Poland

Identifier

ORL-000000183

Address

ul. Szafirowa 15 lok. 45, 20-573, Poland

Departments

Dermatology
Lublin
LUXDERM Specjalistyczny Gabinet
Luxderm Specjalistyczny Gabinet Dermatologiczny Prof. dr hab n.med. Dorota Krasowska
Luxderm Specjalistyczny Gabinet Dermatologiczny Prof.dr.hab.n.med. Dorota Krasowska
N/A
NA

Clinical trials at this site (10)

Search interface

Phase 2 Study of LAD191 in Adults With Hidradenitis Suppurativa Recruiting

2025-521293-34-00 Moderate-to-severe hidradenitis suppurativa 4 2025-12-09
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab in Patients with Prurigo No… Ended

2023-510279-80-00 Prurigo nodularis 4 2024-09-25
A Study to Evaluate the Safety and Effectiveness of APG777 in Subjects with Atopic Dermatitis Ended

2024-511260-84-00 Atopic Dermatitis 4 2024-09-03
Selective Treatment of Oral Povorcitinib in Hidradenitis Suppurativa Long-Term Extension Study (STOP-HS LTE) Ended

2023-507204-31-00 Hidradenitis Suppurativa 5 2024-07-26
Efficacy and Safety of Methotrexate versus Placebo in Adults with Atopic Dermatitis Ended

2023-504443-13-00 moderate to severe atopic dermatitis 5 2024-01-29
Study to see how good and safe Tildrakizumab is in children aged 6 to under 18 years of age with skin patches Ended

2023-504447-14-00 Treatment of pediatric subjects with moderate to severe 10 2021-07-29
A Study to Evaluate the Safety and Effectiveness of ADX-914 in Subjects with Moderate to Severe Atopic Dermatitis Ended

2023-510238-10-00 Moderate to Severe Atopic Dermatitis 4 2024-05-13
A Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis Ended

2022-502461-23-00 Prurigo Nodularis 5 2024-02-15
Hidradenitis Suppurativa Phase 3 Study of Izokibep Ended

2022-503160-33-00 Hidradenitis Suppurativa 5 2023-12-15
A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (S… Ended

2022-501753-36-00 Hidradenitis Suppurativa 5 2023-06-02